What Rocket Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 1 |
| Sells | 7 | 25 |
| Total trades | 9 | 42 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 223,313 | 1,429,618 |
| Disposed | 125,977 | 258,044 |
| Net activity | +97,336 | +1,171,574 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Wilson Martin | General Counsel | Sep 11 | Open-market sale · S | −75,364 | $3.40 | −$256K | 598,489 |
| Wilson Martin | General Counsel | Aug 18 | Open-market sale · S | −631 | $3.38 | −$2.13K | 673,853 |
| Shah Gaurav | CEO | Aug 18 | Open-market sale · S | −2,293 | $3.38 | −$7.75K | 1,056,594 |
| Wilson Martin | General Counsel | Aug 13 | Open-market sale · S | −3,493 | $3.38 | −$11.8K | 674,484 |
| Shah Gaurav | CEO | Aug 13 | Open-market sale · S | −2,837 | $3.38 | −$9.59K | 1,058,887 |
| Chaudhuri Sarbani | See Remarks | Aug 11 | Open-market sale · S | −4,701 | $3.50 | −$16.4K | 262,809 |
| Stevens Christopher James | Chief Operating Officer | Aug 11 | Sale for tax withholding · S | −36,658 | $3.50 | −$128K | 505,784 |
| Stevens Christopher James | Chief Operating Officer | Aug 03 | Grant / award · A | +73,313 | — | — | 542,442 |
| Southwell David P | Director | Aug 03 | Other Transaction · J | +150,000 | — | — | 204,522 |
| Boess Carsten | Director | Jun 18 | Grant / award · A | +22,862 | — | — | 52,862 |
| Southwell David P | Director | Jun 18 | Grant / award · A | +22,862 | — | — | 54,522 |
| Malik Fady Ibraham | Director | Jun 18 | Grant / award · A | +22,862 | — | — | 52,862 |
| Dolsten Mikael | Director | Jun 18 | Grant / award · A | +22,862 | — | — | 67,082 |
| Fong Peter | Director | Jun 18 | Grant / award · A | +22,862 | — | — | 76,195 |
| Wong Roderick | Director | Jun 18 | Grant / award · A | +27,832 | — | — | 75,499 |
| Shah Gaurav | CEO | May 21 | Open-market sale · S | −55,684 | $3.09 | −$172K | 1,061,724 |
| Shah Gaurav | CEO | May 21 | Exercise / conversion · M | +76,490 | $1.69 | +$129K | 1,117,408 |
| Militello John | See Remarks | May 19 | Open-market sale · S | −384 | $3.01 | −$1.16K | 89,780 |
| Wilson Martin | General Counsel | May 19 | Open-market sale · S | −662 | $3.01 | −$2K | 677,977 |
| Shah Gaurav | CEO | May 19 | Open-market sale · S | −2,409 | $3.01 | −$7.26K | 1,040,918 |
Loading...
